Department of Nuclear Medicine, PET-CT Center and Thyroid Unit, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
Head Neck. 2011 Apr;33(4):552-6. doi: 10.1002/hed.21490. Epub 2010 Sep 7.
The purpose of this study was to evaluate the relationship between postsurgical neck (⁹⁹m) technetium ((⁹⁹m) Tc)-pertechnetate uptake and the rate of successful remnant ablation after radioiodine treatment in patients with differentiated thyroid carcinoma (DTC).
Retrospectively enrolled were 232 patients with DTC who underwent total thyroidectomy and fixed activity ablation with 3.7 GBq ¹³¹I. The (⁹⁹m) Tc scans were performed on all patients before ¹³¹I administration. Thyroid ablation was assessed after 6 to 12 months by thyroid-stimulating hormone (TSH)-stimulated ¹³¹I-WBS and thyroglobulin measurement. The rate of successful ablation, occurrence of radioiodine-induced thyroiditis, and length of hospitalization were correlated with the (⁹⁹m) Tc-pertechnetate scintigraphy results.
A (⁹⁹m) Tc uptake was significantly lower in ablated versus nonablated patients (p < .001). High (⁹⁹m) Tc-pertechnetate uptake, especially greater than 1.4%, predicted a high-risk of unsuccessful ablation. Higher (⁹⁹m) Tc-pertechnetate uptake was also related to prolonged hospitalization and the occurrence of radioiodine-induced thyroiditis.
The (⁹⁹m) Tc-pertechnetate scintigraphy is a simple and feasible tool to evaluate thyroid remnants and to predict radioiodine ablation results in patients with DTC.
本研究旨在评估分化型甲状腺癌（DTC）患者手术后颈部（⁹⁹m）锝（⁹⁹m）高锝酸盐摄取与放射性碘治疗后残余消融成功的关系。
回顾性纳入 232 例接受全甲状腺切除术和 3.7GBq¹³¹I 固定活度消融的 DTC 患者。所有患者在¹³¹I 给药前均行（⁹⁹m）Tc 扫描。甲状腺消融在 6 至 12 个月后通过促甲状腺激素（TSH）刺激¹³¹I-WBS 和甲状腺球蛋白测量进行评估。消融的成功率、放射性甲状腺炎的发生和住院时间与（⁹⁹m）Tc-高锝酸盐闪烁扫描结果相关。
与未消融患者相比，消融患者的（⁹⁹m）Tc 摄取明显降低（p<0.001）。高（⁹⁹m）Tc-高锝酸盐摄取，特别是大于 1.4%，预测消融不成功的风险较高。较高的（⁹⁹m）Tc-高锝酸盐摄取也与住院时间延长和放射性甲状腺炎的发生有关。
（⁹⁹m）Tc-高锝酸盐闪烁扫描是一种评估甲状腺残余物和预测 DTC 患者放射性碘消融结果的简单可行的工具。
